Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

BIIB

Biogen Inc

Mar 11 • 04:00PM ET

143.66

Dollar change -7.05
Percentage change -4.68	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO QQQ VO COWZ SPY IVV VTV XLV RSP

Index	NDX, S&P 500	P/E	12.85	EPS (ttm)	11.18	Insider Own	0.52%	Shs Outstand	145.80M	Perf Week	0.71%
Market Cap	21.03B	Forward P/E	9.06	EPS next Y	15.86	Insider Trans	-1.15%	Shs Float	145.61M	Perf Month	1.63%
Income	1.63B	PEG	-	EPS next Q	3.56	Inst Own	91.01%	Short Float	2.55%	Perf Quarter	-9.80%
Sales	9.27B	P/S	2.27	EPS this Y	-3.07%	Inst Trans	2.17%	Short Ratio	2.37	Perf Half Y	-28.46%
Book/sh	114.65	P/B	1.25	EPS next Y	-0.68%	ROA	5.95%	Short Interest	3.72M	Perf Year	-34.51%
Cash/sh	16.23	P/C	8.85	EPS next 5Y	-0.06%	ROE	10.36%	52W Range	128.51 - 238.00	Perf YTD	-6.06%
Dividend Est.	-	P/FCF	7.73	EPS past 5Y	-18.66%	ROI	7.56%	52W High	-39.64%	Beta	0.03
Dividend TTM	-	Quick Ratio	0.90	Sales past 5Y	-5.94%	Gross Margin	67.37%	52W Low	11.79%	ATR (14)	5.01
Dividend Ex-Date	-	Current Ratio	1.35	EPS Y/Y TTM	39.71%	Oper. Margin	22.49%	RSI (14)	50.22	Volatility	4.52% 3.52%
Employees	7605	Debt/Eq	0.40	Sales Y/Y TTM	-1.60%	Profit Margin	17.61%	Recom	2.11	Target Price	194.25
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	6.56%	Payout	0.00%	Rel Volume	1.19	Prev Close	150.71
Sales Surprise	1.93%	EPS Surprise	3.26%	Sales Q/Q	1.66%	Earnings	Feb 12 BMO	Avg Volume	1.57M	Price	143.66
SMA20	1.69%	SMA50	-0.42%	SMA200	-21.65%	Trades		Volume	1,857,241	Change	-4.68%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350

Show Previous Ratings

Today 07:47AM	Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR (Clinical Trials Arena)
Mar-11-25 07:30AM	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients (GlobeNewswire)
Mar-04-25 01:49PM	Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion? (Investor's Business Daily)
12:02PM	Tariffs Send Investors to Safety of Food, Drug and Utility Stocks (The Wall Street Journal)
02:11AM	New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach (Pharma Voice)
04:02AM	Loading…
Mar-03-25 04:02AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Feb-28-25 08:23AM	The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease (PR Newswire)
Feb-25-25 12:19PM	Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-24-25 12:39PM	NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects (Benzinga)
Feb-22-25 11:47PM	Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts (Insider Monkey)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga)
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-13-25 02:30PM	Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts (Benzinga)
10:43AM	Loading…
10:43AM	Sage Therapeutics price target lowered to $12 from $14 at Scotiabank (TipRanks)
10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:33AM	Royalty Pharma pays $250m for rights to Biogens lupus drug (Pharmaceutical Technology)
02:08AM	Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges (GuruFocus.com)
12:04AM	Analyst Report: Biogen Inc. (Morningstar Research)
Feb-12-25 11:30PM	Q4 2024 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
04:18PM	Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat (Investor's Business Daily)
01:30PM	Biogen (BIIB) Q4 2024 Earnings Call Transcript (Motley Fool)
01:13PM	Vertiv, Biogen, Super Micro Computer: Market Minute (Yahoo Finance Video)
10:49AM	Q4 2024 SAGE Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:51AM	Biogen expects 2025 profit decline despite strong Q4 (Yahoo Finance Video)
09:39AM	Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma (Benzinga)
09:30AM	Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:41AM	Biogens (NASDAQ:BIIB) Q4 Sales Top Estimates (StockStory)
06:47AM	Loading…
06:47AM	Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition (Reuters)
06:45AM	Why Investors Might Hammer Biogen Despite Its Earnings Beat (Investor's Business Daily)
Feb-11-25 04:28PM	5 Struggling Stocks That Might Be Buys (Barrons.com)
01:56PM	What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday? (Benzinga)
09:49AM	Bernstein starts Biogen at market-perform, notes near term uncertainty (Investing.com)
08:01AM	Biogen (BIIB) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-08-25 09:20AM	Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-07-25 09:15AM	Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
07:32AM	Genentech eyes lupus market for Gazyva with positive Phase III data readout (Pharmaceutical Technology)
Feb-05-25 10:00AM	Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:16AM	Lillys investigational Alzheimers to be investigated in prevention trial (Clinical Trials Arena)
Feb-02-25 08:12AM	Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? (Insider Monkey)
Jan-31-25 06:30AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jan-29-25 12:10PM	Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-28-25 07:28AM	Sage rejects Biogens $469m takeover bid (Pharmaceutical Technology)
Jan-27-25 12:40PM	Sage rebuffs Biogen bid to take it over (BioPharma Dive)
09:28AM	Sage rejects Biogen's $469 million takeover offer, says offer undervalues company (Reuters)
07:12AM	Eisai and Biogens Leqembi sBLA set for Alzheimers maintenance dosing (Pharmaceutical Technology)
07:05AM	FDA clears monthly dosing of Alzheimers drug Leqembi (BioPharma Dive)
Jan-26-25 06:38PM	US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug (Reuters)
06:33PM	FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Jan-23-25 12:06PM	Biogens higher dose Spinraza under review by US and EU regulators (Pharmaceutical Technology)
09:46AM	Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell? (Investor's Business Daily)
07:30AM	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA (GlobeNewswire)
Jan-22-25 12:03PM	Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk (Yahoo Finance)
Jan-21-25 06:05AM	Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma (The Wall Street Journal)
Jan-15-25 06:52AM	At JPM, Biogen CEO tries to take down the deal temperature (BioPharma Dive)
06:26AM	Federal watchdog cites concerns with FDAs accelerated approval process (BioPharma Dive)
Jan-14-25 06:00PM	Biogen CEO sees no burning need for more acquisitions (Reuters)
09:41AM	Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist (TipRanks)
09:40AM	Biogen bid for Sage does not change narrative, says BMO Capital (TipRanks)
09:04AM	FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi (Benzinga)
08:06AM	Eisai and Biogens subcutaneous Leqembi set for FDA review (Pharmaceutical Technology)
Jan-13-25 07:05PM	FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
03:12PM	Biogen proposes acquisition of partner Sage Therapeutics (Pharmaceutical Technology)
11:57AM	Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More (Investopedia)
09:56AM	Biogen Wants to Buy Its Partner Sage for Almost No Premium (Barrons.com)
09:51AM	Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid (Investopedia)
09:38AM	Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? (Benzinga)
07:24AM	Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen (Barrons.com)
07:07AM	Biogens cold and calculated offer to buy Sage receives a mixed reaction on Wall Street (BioPharma Dive)
Jan-10-25 06:49PM	Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (Business Wire)
06:37PM	Biogen proposes to buy remaining stake in Sage in $442 million deal (Reuters)
09:02AM	Heres Why ClearBridge Growth Strategy Sold Biogen (BIIB) (Insider Monkey)
06:43AM	Pfizers PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets (BioPharma Dive)
06:25AM	Alzheimers Drugs Eyed as Next Big Obesity-Like Opportunity (Bloomberg)
Jan-09-25 08:00AM	Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory? (Investor's Business Daily)
Jan-08-25 04:40PM	Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)s Struggles with Alzheimers and MS Challenges? (Insider Monkey)
Jan-04-25 07:45AM	These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 (Motley Fool)
Jan-02-25 12:03PM	Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs? (Investor's Business Daily)
09:25AM	Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges (Investing.com)
Jan-01-25 09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
09:37AM	The 5 worst performing stocks on the Nasdaq 100 in 2024 (TheStreet)
Dec-28-24 04:49PM	Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 (Insider Monkey)
Dec-23-24 05:07AM	Biogen Faces Multiple Analyst Downgrades in December 2024 (GuruFocus.com)
Dec-20-24 09:44AM	BMO cuts rating on Merck and Biogen, on lack of near term catalyst (Investing.com)
Dec-16-24 01:16PM	Stifel downgrades Biogen on slow Alzheimers drug launch, uncertainty ahead (Investing.com)
10:26AM	Netflix, Ford, Biogen: Trending tickers (Yahoo Finance Video)
Dec-13-24 08:00AM	CMS says private Medicare plans cant automatically deny Biogens ALS drug (BioPharma Dive)
Dec-11-24 07:10AM	Biogen reinstated with a Neutral at BofA (TipRanks)
Dec-09-24 01:44PM	Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown (Benzinga)
12:27PM	Biogen cut at Jefferies as '2025 has a tough setup' (Investing.com)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 06:31PM	'LEQEMBI' (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico (PR Newswire)
Dec-02-24 07:44AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-28-24 06:08AM	Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? (Insider Monkey)
Nov-27-24 07:31PM	'LEQEMBI' (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea (PR Newswire)
09:15AM	Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? (Insider Monkey)
Nov-26-24 02:23PM	Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy? (Investor's Business Daily)
Nov-22-24 11:00AM	Is Eli Lilly Stock A Sell After Kennedy-Tied Woes Rankled Shares? (Investor's Business Daily)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM

Open in Screener

VSTM

Verastem Inc

Mar 11 • 04:00PM ET

7.15

Dollar change +0.03
Percentage change 0.42	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD AMGN MRK PFE BMY REGN VRTX INCY LUMO SRPT

| Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL UWM URTY

Index	RUT	P/E	-	EPS (ttm)	-3.19	Insider Own	11.29%	Shs Outstand	40.26M	Perf Week	21.19%
Market Cap	318.22M	Forward P/E	-	EPS next Y	-2.56	Insider Trans	-0.28%	Shs Float	39.48M	Perf Month	23.49%
Income	-93.45M	PEG	-	EPS next Q	-0.83	Inst Own	66.22%	Short Float	15.11%	Perf Quarter	36.19%
Sales	10.00M	P/S	31.82	EPS this Y	23.45%	Inst Trans	31.62%	Short Ratio	4.35	Perf Half Y	197.92%
Book/sh	0.27	P/B	26.03	EPS next Y	15.38%	ROA	-61.78%	Short Interest	5.96M	Perf Year	-39.36%
Cash/sh	2.55	P/C	2.81	EPS next 5Y	26.63%	ROE	-136.87%	52W Range	2.10 - 13.52	Perf YTD	38.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.76%	ROI	-148.66%	52W High	-47.12%	Beta	0.44
Dividend TTM	-	Quick Ratio	3.23	Sales past 5Y	-47.66%	Gross Margin	99.76%	52W Low	240.48%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	3.23	EPS Y/Y TTM	21.19%	Oper. Margin	-1145.05%	RSI (14)	73.51	Volatility	10.18% 6.62%
Employees	73	Debt/Eq	1.29	Sales Y/Y TTM	-	Profit Margin	-934.54%	Recom	1.00	Target Price	12.57
Option/Short	Yes / Yes	LT Debt/Eq	0.95	EPS Q/Q	20.28%	Payout	-	Rel Volume	0.58	Prev Close	7.12
Sales Surprise	16.81%	EPS Surprise	18.68%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	1.37M	Price	7.15
SMA20	19.51%	SMA50	24.05%	SMA200	77.51%	Trades		Volume	793,420	Change	0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform

Show Previous Ratings

Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%
07:30AM	Loading…
Jan-14-25 07:30AM	Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China (Business Wire) -5.62%
Jan-13-25 07:30AM	Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 (Business Wire) -6.81%
Jan-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.79%
Dec-31-24 10:33AM	Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application (GuruFocus.com) +40.87%
Dec-30-24 04:30PM	Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-20-24 07:00AM	Applied Therapeutics Appoints John H. Johnson as Executive Chairman (GlobeNewswire) -5.63%
Dec-18-24 07:30AM	Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire) -7.39%
Nov-26-24 07:00AM	Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-24 05:00PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -6.98%
04:05PM	Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
12:02PM	Loading…
Nov-01-24 12:02PM	Verastem Oncology submits NDA for ovarian cancer treatment (Pharmaceutical Technology)
Oct-31-24 04:01PM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
07:30AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Oct-17-24 01:00AM	Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting (Business Wire) -20.12%
Oct-09-24 06:00AM	Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting (Business Wire)
Oct-07-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-10-24 04:05PM	Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference (Business Wire) +8.76%
07:30AM	Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting (Business Wire)
Sep-03-24 07:30AM	Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 (Business Wire)
Aug-08-24 06:18PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-29-24 04:01PM	Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer (Business Wire) -7.43%
Jul-23-24 11:20PM	Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire) -17.55%
04:05PM	Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire)
Jul-15-24 11:42AM	Verastem (VSTM) Begins Dosing in Solid Tumors Study in China (Zacks)
04:52AM	Loading…
04:52AM	Verastem announces dosing of first patient in trial of KRAS G12D inhibitor (Clinical Trials Arena)
Jul-12-24 07:30AM	Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics (Business Wire) +12.75%
Jul-08-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-24 07:30AM	Verastem Oncology Announces Addition to Russell 3000 and Russell Microcap Indexes (Business Wire) +9.06%
Jun-19-24 07:00AM	GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation (PR Newswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-06-24 06:45AM	7 F-Rated Stocks to Avoid at All Costs in June (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-24-24 12:28PM	Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data (Zacks) -66.17%
11:43AM	Is the Stock Market Open on Memorial Day 2024? (InvestorPlace)
11:23AM	7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split (InvestorPlace)
11:01AM	NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial (InvestorPlace)
10:45AM	What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? (Benzinga)
10:39AM	Why Is Verastem (VSTM) Stock Down 62% Today? (InvestorPlace)
08:47AM	ASCO 2024: Verastems combo therapy for pancreatic cancer hits early trial success (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:00AM	Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
May-23-24 05:01PM	Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer? (Business Wire)
May-09-24 10:58PM	VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 (InvestorPlace)
04:56PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
May-07-24 07:30AM	Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48% +7.51%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-23 07:00AM	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics (Business Wire)
Dec-13-23 09:08AM	3 Off-the-Beaten-Path Stocks Poised for Substantial Growth (InvestorPlace) +10.67%
07:00AM	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -5.66%
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire) -7.85%
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire) +125.55%
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Feb 04 '25	Sale	5.70	858	4,891	346,723	Feb 05 04:30 PM
Paterson Dan	President and CEO	Jan 13 '25	Sale	5.24	8,568	44,896	347,581	Jan 14 04:30 PM
Dan Paterson	Officer, Director	Jan 13 '25	Proposed Sale	5.24	8,568	44,909		Jan 13 05:03 PM
Calkins Daniel	Chief Financial Officer	Jan 06 '25	Sale	6.94	6	42	47,639	Jan 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '24	Sale	4.34	65	282	47,396	Dec 26 04:30 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '24	Sale	3.91	28	109	47,368	Dec 26 04:30 PM
Gagnon Robert E.	Director	Dec 16 '24	Sale	4.54	285	1,294	34,607	Dec 20 04:32 PM
Gagnon Robert E.	Director	Dec 19 '24	Sale	4.37	130	568	34,477	Dec 20 04:32 PM
Stuglik Brian M	Director	Dec 16 '24	Sale	4.54	595	2,701	95,514	Dec 20 04:31 PM
Stuglik Brian M	Director	Dec 19 '24	Sale	4.37	334	1,460	95,180	Dec 20 04:31 PM
Paterson Dan	President and CEO	Dec 16 '24	Sale	4.54	244	1,108	231,332	Dec 20 04:30 PM
Paterson Dan	President and CEO	Dec 19 '24	Sale	4.37	183	800	231,149	Dec 20 04:30 PM
Paterson Dan	President and CEO	Nov 05 '24	Sale	3.84	812	3,118	231,576	Nov 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Oct 07 '24	Sale	2.86	6	17	47,461	Oct 09 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 20 '24	Sale	2.80	65	182	47,495	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '24	Sale	2.68	28	75	47,467	Sep 24 04:30 PM
Gagnon Robert E.	Director	Sep 19 '24	Sale	2.79	131	365	34,892	Sep 20 06:01 PM
Paterson Dan	President and CEO	Sep 19 '24	Sale	2.79	184	513	232,388	Sep 20 06:01 PM
Stuglik Brian M	Director	Sep 19 '24	Sale	2.79	336	937	96,109	Sep 20 06:00 PM
Gagnon Robert E.	Director	Sep 16 '24	Sale	2.80	287	804	35,023	Sep 18 04:30 PM
Stuglik Brian M	Director	Sep 16 '24	Sale	2.80	600	1,680	96,445	Sep 18 04:30 PM
Paterson Dan	President and CEO	Sep 16 '24	Sale	2.80	246	689	232,572	Sep 18 04:30 PM
Paterson Dan	President and CEO	Aug 05 '24	Sale	2.16	3,245	7,009	232,818	Aug 07 04:18 PM
Calkins Daniel	Chief Financial Officer	Jul 09 '24	Sale	2.62	7	18	47,560	Jul 11 07:00 AM
Calkins Daniel	Chief Financial Officer	Jun 24 '24	Sale	3.15	28	88	47,290	Jun 26 04:30 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '24	Sale	3.16	67	212	47,318	Jun 20 08:30 PM
Gagnon Robert E.	Director	Jun 17 '24	Sale	3.49	283	988	27,108	Jun 20 08:29 PM
Gagnon Robert E.	Director	Jun 20 '24	Sale	3.21	131	421	35,310	Jun 20 08:29 PM
Paterson Dan	President and CEO	Jun 17 '24	Sale	3.49	244	852	86,246	Jun 20 08:28 PM
Paterson Dan	President and CEO	Jun 20 '24	Sale	3.21	183	587	236,063	Jun 20 08:28 PM
Stuglik Brian M	Director	Jun 17 '24	Sale	3.49	593	2,070	89,047	Jun 20 08:27 PM
Stuglik Brian M	Director	Jun 20 '24	Sale	3.21	335	1,075	97,045	Jun 20 08:27 PM
Calkins Daniel	Chief Financial Officer	Apr 05 '24	Sale	10.87	6	65	8,535	Apr 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 25 '24	Sale	12.02	25	300	8,541	Mar 27 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '24	Sale	11.07	55	609	8,566	Mar 21 04:31 PM
Gagnon Robert E.	Director	Mar 18 '24	Sale	10.71	283	3,031	27,521	Mar 20 05:36 PM
Gagnon Robert E.	Director	Mar 19 '24	Sale	10.38	130	1,349	27,391	Mar 20 05:36 PM
Paterson Dan	President and CEO	Mar 18 '24	Sale	10.71	244	2,613	86,672	Mar 20 05:34 PM
Paterson Dan	President and CEO	Mar 19 '24	Sale	10.38	182	1,889	86,490	Mar 20 05:34 PM
Stuglik Brian M	Director	Mar 18 '24	Sale	10.71	537	5,751	89,913	Mar 20 05:32 PM
Stuglik Brian M	Director	Mar 19 '24	Sale	10.38	273	2,834	89,640	Mar 20 05:32 PM

BIIB

Biogen Inc

VSTM

Verastem Inc

Upgrade your FINVIZ experience